Similar articles

• Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

  Fernandez JS, Sadaniantz A. Fernandez JS, et al. Med Health R I. 2001 Feb;84(2):37-43. Med Health R I. 2001. PMID: 11272658 Review. No abstract available.
• The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.

  Nguyen-Ho P, Levine GN. Nguyen-Ho P, et al. Panminerva Med. 2002 Jun;44(2):115-22. Panminerva Med. 2002. PMID: 12032429 Review.
• Management of acute coronary syndromes.

  Schulman SP, Fessler HE. Schulman SP, et al. Am J Respir Crit Care Med. 2001 Sep 15;164(6):917-22. doi: 10.1164/ajrccm.164.6.2101047. Am J Respir Crit Care Med. 2001. PMID: 11587971 Review. No abstract available.
• [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention].

  Kakuta T, Kishi Y, Numano F. Kakuta T, et al. Nihon Rinsho. 1998 Oct;56(10):2630-4. Nihon Rinsho. 1998. PMID: 9796330 Review. Japanese.
• Clinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevation.

  Otterstad JE, Fox KA. Otterstad JE, et al. Scand Cardiovasc J. 2002 Sep;36(5):261-71. doi: 10.1080/140174302320774447. Scand Cardiovasc J. 2002. PMID: 12470391 Review. No abstract available.